Sort
4,870 grants matching “glp 1”
IND-enabling toxicology studies to reach IND approval for a proprietary biologic to treat oral mucositis in cancer patients
$1,230,285Christian Young · Allander Biotechnologies, Inc. · SB1 · FY2024 · DE
Development of a universal gene therapy for hemophilia A or B with or without inhibitors
$1,230,198Paris Margaritis · Geneventiv Therapeutics, Inc. · R44 · FY2024 · HL
Novel Antiangiogenic Peptides for Treatment of Exudative AMD
$1,230,010Nader Sheibani · University Of Wisconsin-Madison · R24 · FY2014 · EY
Preclinical Development of a Novel Therapeutic to Rejuvenate Aging Muscle Stem Cells and Enhance Muscle Strength and Function Post Hip Fracture
$1,229,027Harshini Neelakantan · Ridgeline Therapeutics, Llc · U44 · FY2021 · AG
A novel vaccine against multidrug-resistant gonorrhea
$1,227,829Sanjay Ram · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · AI
3D Printed Silicon Nitride Porous PEEK Composite Spinal Cages for Anti-Infection
$1,227,401Ryan Bock · Sintx Technologies, Inc. · R44 · FY2023 · AR
Neuroprotective role of GLP-1 receptor agonists (Neurodegenerative disorders & Alzheimer's disease)
$1,225,528Nigel H. Greig · National Institute On Aging · ZIA · FY2023 · AG
Regulators of Food Intake
$1,225,214Jonathan Krakoff · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2022 · DK
Nonclinical development of Nervelight, an intra-operative peripheral nerve imaging agent
$1,220,153Stephen B Kahl · Manzanita Pharmaceuticals, Inc. · R44 · FY2017 · CA
Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry
$1,217,955Jose M Mejia Oneto · Shasqi, Inc. · R44 · FY2024 · CA
Targeting inflammation and oxidative stress to treat acute lung injury with CNP-miR146a
$1,216,721David Jackson · Ceria Therapeutics, Inc. · R44 · FY2024 · HL
Novel Antiangiogenic Peptides for Treatment of Exudative AMD
$1,213,468Nader Sheibani · University Of Wisconsin-Madison · R24 · FY2017 · EY
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses
$1,208,817John H Eldridge · Profectus Biosciences, Inc. · R01 · FY2016 · AI
Preclinical Development of Flagellin as a Mucosal Adjuvant in Biodefense Vaccines
$1,208,308Steven B. Mizel · Wake Forest University Health Sciences · U01 · FY2006 · AI
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse
$1,208,298Erica J Young · Myosin Therapeutics Inc. · R44 · FY2023 · DA
Development of a first-in-class nonmuscle myosin II inhibitor to prevent substance use disorder relapse
$1,208,298Erica J Young · Myosin Therapeutics Inc. · R44 · FY2022 · DA
Broad spectrum antibacterials selectively targeting an un-drugged site on the ribosome
$1,206,566Charles Testa · Curza Inc · R01 · FY2019 · AI
Development of a novel adjuvant for vaccine sparing
$1,203,147Sara Lustigman · New York Blood Center · R01 · FY2014 · AI
Alzheimer's Disease Therapeutic
$1,202,600Trevor P. Castor · Aphios Corporation · R44 · FY2011 · AG
Novel Adjunctive Therapies for NeuroAIDS
$1,199,772Harris A Gelbard · University Of Rochester · P01 · FY2010 · MH
Development of a novel adjuvant for vaccine sparing
$1,197,649Sara Lustigman · New York Blood Center · R01 · FY2015 · AI
A Pan-Dengue Virus Immunotherapeutic for Prevention and Treatment
$1,197,162Leslie S Johnson · Macrogenics, Inc. · R01 · FY2011 · AI
Clinical and Informatics Research on Large Clinical Databases
$1,196,486Clement McDonald · National Library Of Medicine · ZIA · FY2025 · LM
Long-Acting G-CSF Analog for Treating ARS
$1,196,000George Norbert Cox · Bolder Biotechnology, Inc. · R44 · FY2015 · AI
Human Antibody Therapeutics Against Anthrax
$1,194,683Katherine S Bowdish · Alexion Pharmaceuticals, Inc. · U01 · FY2006 · AI